Capricor Therapeutics (CAPR) shares soared 5.3% in the last trading session to close at $6.52. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1% loss over the past four weeks.The sharp rise in CAPR shares can be attributed to the company’s encouraging regulatory update on its Deramiocel program for Duchenne muscular dystrophy. Following a Type A meeting with the FDA, the company received guidance outlining a pathway toward a pot ...